Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib

Frontiers in Oncology

Oncology

Farouq Alguayn¹  Wafeek Alguayn²  Betsy Giles³  Hadel Alsana⁴  Nir Peled⁵  Laila C. Roisman⁵  Waleed Kian⁵  Bilal Krayim⁵  Ofer Purim⁵ 

[1] Barzilai Medical Center, Department of Intensive Care, Ashkelon, Israel and Soroka Medical Center, Department of Neurosurgery, Ben-Gurion University, Beer-Sheva, Israel;Division of Pediatric and Congenital Cardiac Surgery, Schneider Children's Medical Center of Israel, Petah Tikva, Israel;Medical School of International Health, Faculty of Health Sciences at Ben-Gurion University, Beer-Sheva, Israel;Pulmonology Department, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel;The Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel;

关键词: EGFR;    L833V;    V834L;    compound mutations;    lung cancer;    CEP85L-ROS1 fusion;    MKRN1-BRAF;    MET amplification;   

DOI  :  10.3389/fonc.2023.1124949

 received in 2022-12-15, accepted in 2023-01-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

Lung cancer is the most common cancer-related cause of death worldwide, most of which are non-small cell lung cancers (NSCLC). Epidermal growth factor receptor (EGFR) mutations are common drivers of NSCLC. Treatment plans for NSCLC, specifically adenocarcinomas, rely heavily on the presence or absence of specific actionable driver mutations. Liquid biopsy can guide the treatment protocol to detect the presence of various mechanisms of resistance to treatment. We report three NSCLC EGFR mutated cases, each treated with Osimertinib in a combination therapy regimen to combat resistance mechanisms. The first patient presented with EGFR L858R/L833V compound mutation with MET amplification alongside CEP85L-ROS1 fusion gene, the second with EGFR exon 19del and MKRN1-BRAF fusion, and the last EGFR L858R/V834L compound mutation with MET amplification. Each regimen utilized a tyrosine kinase inhibitor or monoclonal antibody in addition to osimertinib and allowed for a prompt and relatively durable treatment response.

【 授权许可】

Unknown   
Copyright © 2023 Kian, Krayim, Alsana, Giles, Purim, Alguayn, Alguayn, Peled and Roisman